Mitocnol Research
Here you will find a list of significant research which is relevant to Mitocnol. If you know about studies which should also be listed here then please contact us.
(1)
DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348:2656-2668
(2)
Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
(3)
Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
(4)
Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
(5)
Walker UA, Koch E, Venhoff N, Klinker H, Langman P, Zilly M et al. Uridine prevents and treats mtDNA-depletion by NRTI-pyrimidine analogues and fully restores mitochondrial function. Antivir Ther 2003; 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris.
(6)
Venhoff N, Setzer B, Lebrecht D, Walker UA. Dietary supplements in the treatment of NRTI-related mitochondrial toxicity. AIDS 2002; 16:800-802.
(7)
Walker UA, Byrne E. The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neurol Scand 1995; 92:273-280.
(8)
Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrobial Agents & Chemotherapy 1988; 32(7):997-1001.
(9)
Cui L, Locatelli L, Xie MY, Sommadossi JP. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther 1997; 280:1228-1234.
(10)
Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47:273-289.
(11)
Setzer B, Schlesier M, Thomas AK, Walker UA. Immunosuppressive effect of mtDNA-depletion by d-drugs in healthy human-lymphocytes. Antivir Ther 2003; 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris.
(12)
Eva Koch, Josef Schneider, Roland Weis, Björn Penning and Ulrich A. Walker. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antiviral Therapy 2003; 8: 485-487.
(13)
Ulrich A. Walker, Nils Venhoff, Eva koch, Manfred Olschewski, Josef Schneider and Bernard Setzer. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antiviral Therapy 2003; 8: 87-94.
(14)
UA. Walker, P. Langmann, N. Miehle, M. Zilly, H. Klinker and F. Petschner. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004, 18: 1085-1086.
(15)
UA. Walker, M Auclair, D Lebrecht, M Kornprobst, J Capeau and M Caron. Uridine abrogates the adverse effects of stavudine and zalcitabine on adipose cell functions. Antiviral Therapy, 2004 9: L 10-L11.
(16)
B Setzer, M Schlesier and UA Walker. Functional impairment of NRTI-related mitochondrial DNA-depletion in primary human T-lymphocytes. Antiviral Therapy, 2004 9: L42.
(17)
N Venhoff, M Zilly, D Lebrecht, D Schirmer, H Klinker, J Thoden, P Langmann, and UA Walker. Uridine pharmacokinetics of Mitocnol, a sugar cane extract. Antiviral Therapy 2004 9: L21-L22.
(18)
UA. Walker. Mitochondriale Toxizität von Nukleosidanaloga in HIV.NET 2005; C. Hoffmann und BS Kamps (Hrsg). Steinhäuser Verlag, Wuppertal. (2005)
(19)
Keilbaugh,S.A.; Hobbs,G.A.; Simpson,M.V. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Molecular Pharmacology 1993, 44: 702-706.
(20)
Fat loss may be restored with dietary supplement. Keith Alcorn, Monday, November 14, 2005
www.aidsmap.com/en/news/104869B7-DFA8-4768-ADB5-DD00A4DB77F3.asp
(22)
Improving Lipoatrophy: Uridine and Pravastatin studies raise hope of new interventions to combat fat loss. Dr Graeme Moyle, Chelsea and Westminster Hospital, London.
www.natap.org/2005/adverse/adverse_3.htm
(23)
Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther. 2005;10 Suppl 2:M117-23
www.ncbi.nlm.nih.gov/entrez/query.fcgi
(24)
McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion. 2004 Jul;4(2-3):111-8.
www.ncbi.nlm.nih.gov/entrez/query.fcgi
(25)
Joel A. Saydoff, Rolando A.G. Garcia, Susan E. Browne, Liansheng Liu, Jin Sheng, Denise Brenneman, Zhongyi Hu, Sylvain Cardin, Alexis Gonzalez, Reid W. von Borstel, Jason Gregorio, Holly Burr, and M. Flint Beal
Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease
| 
